BG
CRSP icon

Bellevue Group’s CRISPR Therapeutics CRSP Stock Holding History

Bellevue Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Buy
5,818
+802
+16% +$42.3K 0.01% 121
2026
Q1 		$239K Buy
5,016
+3,136
+167% +$165K 0.01% 131
2025
Q4 		$98.6K Buy
+1,880
New +$113K ﹤0.01% 163
2024
Q4 		– Sell
-610,000
Closed -$28.7M – 163
2024
Q3 		$28.7M Sell
610,000
-7,649
-1% -$388K 0.46% 63
2024
Q2 		$33.4M Sell
617,649
-2,301
-0.4% -$133K 0.54% 53
2024
Q1 		$42.3M Sell
619,950
-280,450
-31% -$20.1M 0.64% 49
2023
Q4 		$56.4M Buy
900,400
+2,000
+0.2% +$111K 0.86% 34
2023
Q3 		$40.8M Sell
898,400
-900
-0.1% -$46.5K 0.66% 47
2023
Q2 		$50.5M Sell
899,300
-500
-0.1% -$28.4K 0.72% 45
2023
Q1 		$40.7M Sell
899,800
-11,905
-1% -$578K 0.59% 53
2022
Q4 		$37.1M Sell
911,705
-16,600
-2% -$881K 0.49% 61
2022
Q3 		$60.7M Buy
928,305
+6,300
+0.7% +$457K 0.87% 39
2022
Q2 		$56M Sell
922,005
-4,900
-0.5% -$288K 0.79% 41
2022
Q1 		$58.2M Sell
926,905
-47,779
-5% -$3M 0.68% 52
2021
Q4 		$73.9M Hold
974,684
– – 0.76% 45
2021
Q3 		$109M Buy
974,684
+7,800
+0.8% +$980K 1.11% 28
2021
Q2 		$157M Sell
966,884
-11,500
-1% -$1.4M 1.53% 16
2021
Q1 		$119M Buy
978,384
+68,700
+8% +$10.4M 1.26% 24
2020
Q4 		$139M Sell
909,684
-39,578
-4% -$4.68M 1.6% 15
2020
Q3 		$79.4M Buy
949,262
+148,800
+19% +$13.2M 1.1% 27
2020
Q2 		$58.8M Hold
800,462
– – 0.83% 35
2020
Q1 		$33.9M Buy
800,462
+70,000
+10% +$3.61M 0.66% 43
2019
Q4 		$44.5M Sell
730,462
-106,700
-13% -$5.83M 0.71% 41
2019
Q3 		$34.3M Buy
837,162
+26,700
+3% +$1.28M 0.64% 42
2019
Q2 		$38.2M Buy
+810,462
New +$32.4M 0.65% 40

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bellevue Group's CRSP Position: Q2 2026 in Review

Bellevue Group increased its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, buying an estimated $42.3K and bringing the position to 5,818 shares worth $317K. The position accounts for 0.01% of the portfolio, ranked #121.

Bellevue Group first reported a position in CRSP in Q2 2019 and has held it in 25 quarters since. The position peaked at $157M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bellevue Group held 5,818 shares of CRISPR Therapeutics worth $317K as of Q2 2026.
  • Bellevue Group bought 802 CRISPR Therapeutics shares in Q2 2026, an estimated $42.3K.
  • CRISPR Therapeutics made up 0.01% of Bellevue Group's portfolio in Q2 2026, its #121 holding.
  • Bellevue Group first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Bellevue Group's CRISPR Therapeutics position peaked at $157M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.